BCR-ABL tyrosine kinase inhibitors
A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.
BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).
Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.
BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.
|Drug Name ( View by: Brand | Generic )||Reviews||Ratings|
|dasatinib systemic (Pro, More...)
|imatinib systemic (Pro, More...)
|nilotinib systemic (Pro, More...)
|ponatinib systemic (Pro, More...)
|bosutinib systemic (Pro, More...)
Medical conditions associated with BCR-ABL tyrosine kinase inhibitors: